Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Therapeutics

1,312,962 Journal Article Views | Journal Analytics

Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity?

Submit a Paper



Publication Date: 16 Apr 2009

Type: Review

Journal: Clinical Medicine Insights: Therapeutics

Citation: Clinical Medicine: Therapeutics 2009:1 111-121

Hermann A.M. Mucke

H.M. Pharma Consultancy, Wien (Vienna), Austria.

Abstract

Pulmonary arterial hypertension (PAH) is a deadly and underdiagnosed disease which causes right heart failure secondary to pressure overload resulting from the thickening of the pulmonary artery endothelium, associated with elevated levels of circulating endothelin-1. Sitaxentan was the first endothelin antagonist with high selectivity for receptor subtype A (over subtype ET-B) to gain regulatory approval for the treatment of PAH in major pharmaceutical markets. This review traces the development history of sitaxentan, summarizes the designs and results from its clinical studies, and relates the drug’s profile to that of the two other broadly available endothelin receptor antagonists, bosentan and ambrisentan. All three drugs have comparable therapeutic efficacy in the 6-minute walk test—a frequently employed standard—during the first 3–4 months of therapy. Their performance might differ slightly in other clinically relevant outcome measures, especially in longer-term treatment where fully comparable data have not yet been reported. In clinical trials of up to one year duration the propensity of sitaxentan to induce elevation of liver transaminases and hepatic failure was significantly lower than that of bosentan. As a once-daily oral drug with good tolerability sitaxentan has become a crucial element in the treatment of PAH.


Downloads

PDF  (289.94 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)






What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
I was pleased to serve as a peer reviewer for Clinical Medicine Insights: Therapeutics.  Its scope will hopefully blur some of the lines that still exist between clinical and basic science.  The diligence of the editorial staff ensures the review process is fair, fast and very well-organized.  I highly recommend potential authors and reviewers to submit to and review for this journal.
Dr Sharilyn Almodovar (University of Colorado Denver, Aurora, CO, USA)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results